Blocking α 4 β 7 integrin binding to SIV does not improve virologic control
| Autor: | Brandon F. Keele, Nami Iwamoto, Peter D. Kwong, Jeffrey D. Lifson, Mario Roederer, Susie Min, Jason Gorman, Kaimei Song, Rosemarie D. Mason, Kathryn E. Foulds, Hugh C. Welles, Hannah A. D. King, Aaron J. Belli, James Arthos, Claudia Cicala, Keith A. Reimann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Integrin beta Chains medicine.drug_class Integrin alpha4 T-Lymphocytes Simian Acquired Immunodeficiency Syndrome HIV Infections Biology Antibodies Viral Virus Replication medicine.disease_cause Monoclonal antibody Article 03 medical and health sciences 0302 clinical medicine In vivo medicine Animals Viral Regulatory and Accessory Proteins chemistry.chemical_classification Multidisciplinary Antibodies Monoclonal Gene Products env Viral Load Simian immunodeficiency virus Macaca mulatta Virology Stop codon 030104 developmental biology Viral replication chemistry DNA Viral biology.protein RNA Viral Simian Immunodeficiency Virus Antibody Glycoprotein Viral load 030215 immunology |
| Zdroj: | Science |
| ISSN: | 1095-9203 0036-8075 |
| DOI: | 10.1126/science.aaw7765 |
| Popis: | An antibody is not the antidote An HIV therapeutic that would give long-term remission without sustained antiretroviral therapy (ART) is a long-term goal. Byrareddy et al. [ Science 354 , 197 (2016)] reported that treating simian immunodeficiency virus (SIV)–positive macaques with an antibody against integrin α 4 β 7 during and after ART results in sustained virologic control after stopping all treatment. Three studies in this issue question the reproducibility of that result. Di Mascio et al. sequenced the virus used in the 2016 study and found that it was a variant with a stop codon in the nef gene rather than a wild-type virus. Abbink et al. used the same antibody for α 4 β 7 as before but tested control of a more commonly used pathogenic virus. Iwamato et al. used the same nef -stop virus as in the earlier paper but combined the antibody against the integrin with an antibody against the SIV envelope glycoprotein, which also blocks viral binding of the integrin. None of these three new studies found that treating with the antibody had any effect on virologic control after stopping ART treatment. Science , this issue p. 1025 , p. 1029 , p. 1033 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |